Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chemotherapy-induced nausea and vomiting in the literature: a cross-sectional analysis by time and emetogenicity.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

<i>Supportive Care in What</i>? Myths and Misconceptions That Prevent the Provision of Excellent Cancer Care.

JCO global oncology·2026
Same author

Editorial.

Current opinion in oncology·2026
Same author

Comparing clinical practice guidelines on the prevention and management of chemotherapy-induced hand-foot syndrome.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Multi-disciplinarity in cancer care: a call for a global framework to deliver equitable and effective supportive care.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026

Related Experiment Video

Updated: May 25, 2026

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor
07:45

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor

Published on: June 27, 2011

Colony stimulating factors (CSF) biosimilars. Progress?

Florian Scotté1, Vincent Launay-Vacher, Jean-Baptiste Rey

  • 1European Hospital Georges Pompidou, 20, rue Leblanc, 75015 Paris, France. florian.scotte@egp.aphp.fr

Targeted Oncology
|January 18, 2012
PubMed
Summary

Biosimilars are scientifically developed, equivalent versions of biologic drugs. Understanding these complex biopharmaceuticals is crucial as their market expands, addressing cost-saving goals and scientific scrutiny.

More Related Videos

Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells
12:02

Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells

Published on: November 11, 2021

Related Experiment Videos

Last Updated: May 25, 2026

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor
07:45

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor

Published on: June 27, 2011

Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells
12:02

Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells

Published on: November 11, 2021

Area of Science:

  • Pharmacology
  • Biotechnology
  • Drug Development

Background:

  • Biosimilars are equivalent biologic drugs approved after originator patents expire.
  • They are often perceived as simple copies, primarily for cost reduction.
  • Market expansion of biosimilars raises questions due to potential knowledge gaps.

Purpose of the Study:

  • To discuss the scientific development and regulatory considerations for biosimilar drugs.
  • To address common questions and criticisms surrounding biosimilar market entry.
  • To highlight the importance of product knowledge in the context of biosimilar hematopoietic growth factors.

Main Methods:

  • Review of scientific literature on biosimilar development and regulation.
  • Analysis of regulatory guidelines for biosimilar approval.
  • Discussion of case studies related to biosimilar hematopoietic growth factors.

Main Results:

  • Biosimilars require rigorous scientific development and adherence to strict regulatory standards.
  • Despite being copies, they undergo extensive analytical, clinical, and preclinical testing.
  • The expansion of biosimilar hematopoietic growth factors necessitates a deeper understanding of their scientific basis.

Conclusions:

  • Biosimilars are not mere copies but are complex biopharmaceuticals requiring substantial scientific validation.
  • Addressing knowledge gaps and fostering informed discussions are essential for biosimilar acceptance.
  • Further scientific discourse is needed regarding biosimilar hematopoietic growth factors to ensure appropriate clinical use and market integration.